Tirzepatide vs AHK-Cu
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →AHK-Cu
AHK-Cu (Copper Tripeptide-3, Alanine-Histidine-Lysine Copper) is a copper peptide similar to GHK-Cu but with different properties. It's used for hair growth and skin rejuvenation applications.
Full details →Side-by-Side Comparison
| Aspect | Tirzepatide | AHK-Cu |
|---|---|---|
| Mechanism | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. | The copper-binding tripeptide stimulates collagen synthesis and may promote hair follicle enlargement. Works similarly to GHK-Cu but may have distinct receptor interactions. |
| Typical Dosage | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. | Topical: 0.5-2% concentration in serums for skin or scalp applications. Often combined with other growth factors for hair formulations. |
| Administration | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. | Topical application to skin or scalp. Can be used with microneedling for enhanced penetration. May cause temporary blue-green tint at high concentrations. |
| Side Effects | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. | Generally well-tolerated. May cause skin irritation in sensitive individuals. Temporary discoloration possible. |
| Best For |